Table 1.
Patients’ characteristics
| Name | SS01 | SS1003 | SS201 | SS202 | SS53 | SS03 | SS204 | SS59 |
|---|---|---|---|---|---|---|---|---|
| Gender | F | F | F | F | F | F | F | M |
| Age (yo) | 28 | 69 | 45 | 67 | 56 | 71 | 57 | 76 |
| PTPN22 genotype | CC | CC | CT | CT | CC | CC | CC | CC |
| Antinuclear | 1/1280 | + | + | + | + | + | + | 1/120, nuclear speckled |
| Anti-Ro/anti-La | Both | anti-Ro | − | anti-Ro | anti-Ro | Both | anti-Ro | − |
| Rheumatoid factor | + | + | − | − | − | + | + | − |
| Monoclonal Ig | + | + | − | − | NA | + | + | NA |
| Cryoglobulin | + | + | − | − | NA | + | + | NA |
| Lymphocytic infiltrate | Chisholm stade IV | Chisholm stade IV | Chisholm stade IV | Chisholm stade IV | Focus score per mm−1: 4.0; focal lymphocytic sialadenitis | Chisholm stade IV | Chisholm stade IV | Focus score per mm−1: 1.1; focal lymphocytic sialadenitis |
| Lymphoma | − | MALT lymphoma | MALT lymphoma | − | − | MZ Lymphoma | Lymphocytic lymphoma | − |
| Site of Lymphoma | Parotid gland | Orbit | Bone marrow | Lymph node | ||||
| Medication | steroids, HCQ | rituxan | rituxan | none | none | HCQ | rituxan | none |
F:Female; M:Male; yo: years old, CC: SS patient who did not carry the PTPN22 risk allele, CT: SS patient who carried one PTPN22 risk allele; NA: Not available, MALT: mucosa-associated lymphoid tissue, MZ: Marginal zone, HCQ: Hydroxychloroquine